financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Maintains Hold Opinion On Shares Of West Pharmaceutical Services, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Maintains Hold Opinion On Shares Of West Pharmaceutical Services, Inc.
Apr 25, 2024 9:08 AM

11:55 AM EDT, 04/25/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain a 12-month target price of $375, based on a 2025 P/E of 40.8x, a discount to WST's five-year forward average P/E of 47.0x. We maintain our adjusted EPS estimates of $7.65 for 2024 and $9.20 for 2025. WST posted Q1 EPS of $1.56 vs. $1.98 (-21%), well ahead of the $1.29 consensus. The beat was driven by stronger-than-forecasted sales and margins, as revenue fell 3% to $695M ($20M ahead of consensus) and gross margin contracted 480 bps to 33.1% (110 bps ahead of consensus). WST maintained 2024 revenue guidance of $3.000B-$3.025B, but raised adjusted EPS guidance to $7.63-$7.88 from $7.50-$7.75; the current consensus forecasts are $3.01B and $7.62, respectively. The company reiterated its expectation for stronger organic sales growth in the second half of the year, but we continue to believe caution is warranted, with the stock's valuation appearing fair and near-term comps likely to remain difficult. We maintain a Hold opinion on WST shares, seeing better opportunities across the space.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Raises Opinion On Shares Of Lululemon Athletica To Strong Buy From Buy
Research Alert: CFRA Raises Opinion On Shares Of Lululemon Athletica To Strong Buy From Buy
Mar 22, 2024
08:15 AM EDT, 03/22/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We maintain our 12-month price target of $550, based on 37.9x our FY 25 (Jan.) EPS estimate and below the company's 5-year average forward P/E multiple of 42.7x. We maintain...
Research Alert: CFRA Lowers Opinion On Shares Of Stellantis N.v. To Hold From Buy
Research Alert: CFRA Lowers Opinion On Shares Of Stellantis N.v. To Hold From Buy
Mar 22, 2024
08:25 AM EDT, 03/22/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We increase our 12-month target by $2 to $30, based on a '25 P/E of 4.7x, a justified premium to its historical average forward P/E of 4.3x. Our estimates are...
Research Alert: CFRA Maintains Buy Opinion On Shares Of Apple Inc.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Apple Inc.
Mar 22, 2024
08:20 AM EDT, 03/22/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: The U.S. is suing AAPL, accusing it of monopolizing the smartphone market by citing that AAPL makes it difficult for competitors to integrate with the iPhone, thus raising prices and...
Research Alert: CFRA Lowers Opinion On Shares Of Stellantis N.v. To Hold From Buy
Research Alert: CFRA Lowers Opinion On Shares Of Stellantis N.v. To Hold From Buy
Mar 22, 2024
08:30 AM EDT, 03/22/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We increase our 12-month target by $2 to $30, based on a '25 P/E of 4.7x, a justified premium to its historical average forward P/E of 4.3x. Our estimates are...
Copyright 2023-2024 - www.financetom.com All Rights Reserved